Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

NCT07341867 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma
Triple Negative Breast Cancer
Duffy Blood Group, Chemokine Receptor Gene Mutation
Duffy Blood Group, Chemokine Receptor Gene C.-67T>C

Interventions

DRUG: Dexamethasone
DRUG: Bortezomib
DRUG: LENALIDOMIDE
DRUG: Daratumumab
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Pembrolizumab
DRUG: Cyclophosphamide
DRUG: Doxorubicin

Sponsor

Andrew Hantel, MD